产品详情:
Due to extensive developments in liposome technology in the recent years, a number of liposome-based drug formulations are available in clinic market and many products are under different clinical trials.
Among them, the liposomes
for adriamycin are Doxil®, Myocet®, DaunoXome®;
for Amphotericin B are Abelcet®, Ambisome®, Amphotec®;
The micelle for Paclitaxel are Cynviloq™, Apealea®, Genexol-PM®.
Application:Liposome Preparation
Formulation
Doxil® Adriamycin/mL: HSPC: CHOL: DSPE-mPEG2000=2mg: 9.58mg: 3.19mg: 3.19mg; Excipients: Ammonia Sulfate 2mg Histidine 1.55mg Surcrose 94mg
Ambisome® Amphotericin B: HSPC: CHOL: DSPG=50mg: 213mg: 52mg: 84mg; Excipients: α-Tocopherol 0.64mg Disodium succinate hexahydrate 27mg Sucrose 900mg Water 12mL
Abelcet® Amphotericin B/mL: DMPC: DMPG=5.0mg: 3.4mg: 1.5mg; Excipients: Sodium Chloride: 9.0mg
Amphotec® Amphotericin B: Cholesteryl sodium sulfate: Trometamol =50mg: 26.4mg: 5.64mg; Excipients: Disodium edetate 0.372mg Lactose Monohydrate 950mg Water10ml
Genexol-PM® Paclitaxel: mPEG-PLA=30mg: 150mg
Abraxane® Paclitaxel: Human Albumin=100mg: 900mg
Specification | |||||
Name | Description | Purity | |||
DSPE-mPEG2000 | Methoxypolyethylene glycol DSPE (1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine) | ≥99.0% | |||
HSPC | L-α-phosphatidylcholine, hydro genated (Soy) | ≥99.0% | |||
DSPG | 1,2-Distearoyl-sn-glycero-3-phosphoglycerol, sodium salt | ≥99.0% | |||
DMPC | 1,2-dimyristoyl-sn-glycero-3-phosphocholine | ≥99.0% | |||
DMPG | 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) | ≥99.0% | |||
CHO | Cholesterol | ≥99.0% | |||
Cholesteryl Sulfate | Cholesteryl sodium sulfate | ≥99.0% | |||
PEG-b-PLA | Monomethoxy-Poly(ethylene glycol)-block-poly(d,l-lactic acid) | Quote | |||
Adriamycin | Active ingradient in Doxil®, Myocet®, DaunoXome® | ≥99.0% | |||
Paclitaxel | Active ingradient in Abelcet®, Ambisome®, Amphotec® | ≥99.0% | |||
Amphotericin B | Active ingradient in Cynviloq™, Apealea®, Genexol-PM® | ≥99.0% |